Archive

ISH/BSH 2016: Professor Keith Stewart (Mayo Clinic, USA) discusses his presentation from the presidential session on genomic sequencing in this video. Also included article entitled ‘Genome-guided therapy in multiple myeloma’

Genome-guided therapy in multiple myeloma by Maria Dalby Professor Keith Stewart, Mayo Clinic, Scottsdale, AZ, USA Genomic sequencing of newly-diagnosed and refractory MM patients shows that combination therapy… read more.

ECCO 2016: Dr Charlie Lees (Edinburgh, UK) discusses in the video and article below the factors influencing the decision to stop treatment and discussed whether it may be possible to predict relapse using currently available methods

Stopping drugs – by Maria Dalby Charles Lees (Edinburgh, UK) Medication constitutes a large part of the IBD exposome, and stopping drug treatment should be a therapeutic goal… read more.

BTS 2016: Controversies in UK organ transplantation: have we gone too far in terms of organ quantity at the expense of organ quality? Professor Derek Manas (Newcastle upon Tyne) and Lorna Marson (Edinburgh) discuss in this video the plenary on quantity vs quality.

Controversies in UK organ transplantation: have we gone too far in terms of organ quantity at the expense of organ quality? John Forsythe, Edinburgh Royal Infirmary and Chris… read more.

BTS 2016 Congress Highlights: Video Interview with Lorna Marson (Edinburgh), Professor Nigel Heaton (London), Lisa Burnapp (London), Jayme Locke (Birmingham, AL, USA), Dr Varuna Aluvihare (London), BTS President Professor Derek Manas (Newcastle) and Professor John O’Grady (London).

The BTS Executive and delegates share their highlights of the British Transplantation Society Annual Congress held from 24th-26th February 2016, Glasgow SECC.

ASH 2015: Video Interview by Esther Drain. CDF changes affecting myeloma patients. Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) and Erik Low (Chief Executive Myeloma UK) discuss recent changes in the CDF and how they affect myeloma patients.

ASH 2015: Video Interview by Esther Drain. Myeloma XI initial response data at ASH. Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) discusses the initial response data from Myeloma XI and whether early intensive therapy is the way forward in managing myeloma, with comment also from Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA).

ASH 2015 Video Interview by Esther Drain: Association of gene expression profiling, Interim PET, EBV status and PD-L1 expression in cHL. An interview with Dr Cathy Burton (Clinical Haematologist, Leeds Teaching Hospitals, UK)

ASH 2015 Video Interview by Esther Drain: Is oral as effective as IV or sub cutaneous administration? Professor Philippe Moreau (University Hospital, Nantes, France), Professor Gordon Cook (Leeds Teaching Hospitals, UK) and Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA) discuss whether the trend towards new oral agents for myeloma will mean a choice between efficacy and convenience… or in fact whether both can be achieved

ASH 2015 Video Interview by Esther Drain: Erik Low (Chief Executive Myeloma UK), Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) and Professor Gordon Cook (Leeds Teaching Hospitals, UK) discuss how and when we might expect our patients to have access to the therapies now available to US myeloma patients

ASH 2015: Capitalising on recent advances in HL – R/R HL in the brentuximab vedotin era. Professor Ajay Gopal, Seattle Cancer Care Alliance, WA, USA. Dr Robert Chen, City of Hope, Duarte, CA, USA and Professor John Sweetenham, Huntsman Cancer Institute, Saltlake City, USA., discuss where they see the optimal setting for use of brentuximab vedotin following updates at ASH 2015. Click on the video image to view.

ASH 2015: Checkpoint blockade vision of the future. Professor Stephen Ansell, Mayo Clinic, Rochester, MN, USA discusses the extended follow-up phase 1 nivolumab study in R/R classic HL. Click video image to view.

by Thomas R. Collins: Studies on PD-1 blockade in classical Hodgkin lymphoma are still only entering Phase 2, but the early results and a history of success in… read more.

ASH 2015: Brentuximab vedotin data shows durable CR five years on – is this cure? Dr Robert Chen, (City of Hope, Duarte, CA, USA) discusses the five year survival data presented at ASH; who of the CR patients to watch and wait and who to go onto allo-SCT; and whether these patients are now cured. Click video image to view.

by Thomas R. Collins: Five years after the last patient’s last treatment visit, the final results are in for brentuximab vedotin’s (BV) pivotal Phase 2 study, offering perhaps… read more.